Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 79.78

0.0%

Dec 31 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2733)	7/14/2010 2:01:40 PM
From: Jibacoa	Read Replies (1) of 3722

VVUS has continued it near term UT and seems it wants to retest its May 18 H <g> bigcharts.marketwatch.com VVUS has 4Qs of lower revenues and higher losses,but it is expected that tomorrow the FDA's Endocrinologic and Metabolic Drugs Advisory Committee will review VVUS's marketing application for Qnexa, its formerly formerly VI-0521), for treatment of obesity. Although the FDA is not obligated to follow the recommendation of the expert panel, it usually agrees with its decision.<g> Qnexa has pretty extensive safety and efficacy data and it is expected that the committee should rule in favor of the approval. If this happens, VVUS should have a good spike. So the longs are keeping their fingers crossed.<g> On an eventual Qnexa approval by the FDA, VVUS has some extra room to run.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next